Cargando…

DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience

Diffuse large B-cell lymphoma (DLBCL) represents around one quarter of non-Hodgkin lymphomas in both the United States and globally. The activated B-cell (ABC) subtype of DLBCL is associated with higher relapse rates and a worse prognosis when treated with standard regimens in comparison to other su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knouse, Phillip, Nabrinsky, Edward, Sirota, Ronald L, Hakimian, David, Bitran, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704021/ https://www.ncbi.nlm.nih.gov/pubmed/33269174 http://dx.doi.org/10.7759/cureus.11714

Ejemplares similares

Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
por: Annunzio, Kaitlin, et al.
Publicado: (2022)

Primary Central Nervous System Lymphoma With Systemic Recurrence
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen
por: Kaur, Anahat, et al.
Publicado: (2019)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

A Review of the Abscopal Effect in the Era of Immunotherapy
por: Nabrinsky, Edward, et al.
Publicado: (2022)

Sciatic diffuse large B-cell lymphoma with treatment response to CHOP and radiotherapy
por: Shomal Zadeh, Firoozeh, et al.
Publicado: (2023)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
por: Caixia, LI, et al.
Publicado: (2023)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
por: Wang, Liang, et al.
Publicado: (2021)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms
por: Yu, Haifeng, et al.
Publicado: (2021)

R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma
por: He, Xiao-Hui, et al.
Publicado: (2012)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
por: Painschab, Matthew S, et al.
Publicado: (2021)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
por: Devi, Kanta, et al.
Publicado: (2021)

Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Kim, Joong-Keun, et al.
Publicado: (2014)

Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Cho, Min-Chul, et al.
Publicado: (2018)

Obstructing Duodenal Diffuse Large B-cell Lymphoma with Peritoneal Lymphomatosis with Exceptional Response to R-CHOP
por: Zaarour, Mazen, et al.
Publicado: (2019)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Subtype of the Thyroid
por: Waqar, Syed Hamza Bin, et al.
Publicado: (2021)

R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study
por: Kagami, Yoshitoyo, et al.
Publicado: (2020)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
por: Hong, Junshik, et al.
Publicado: (2014)

The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma
por: Tanimura, Akira, et al.
Publicado: (2018)

miRNA signature associated with R–CHOP refractoriness in patients diagnosed with diffuse large B cell lymphoma
por: Fajardo-Ramirez, Oscar Raul, et al.
Publicado: (2020)

Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
por: Guidez, Stephanie, et al.
Publicado: (2019)

Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma
por: Morita, Yuka, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System
por: Cabrera, María Elena, et al.
Publicado: (2022)

Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
por: Jeong, Jae-Uk, et al.
Publicado: (2017)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B‐cell lymphoma upon start of R‐CHOP
por: Sørensen, Nina, et al.
Publicado: (2018)

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
por: Shen, Rong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7eselngpetsgkpiuu0iumb2cc5